IGF2BP3 and Ewing sarcoma: The BET bromodomain inhibitor JQ1 has been shown to reduce IGF2BP3 expression in neonatal megakaryocytes (Elagib et al, 2017) and Ewing sarcoma cells (Mancarella et al, 2018).